Immuron Limited (AU:IMC) has released an update.
Immuron Limited has reported a substantial increase in sales for their immune supplement Travelan®, with a 154% rise to AUD$3.6 million in global sales and a 234% surge to AUD$2.8 million in Australia for the financial year-to-date March 2024. The company also marked its entry into the US market through Walmart.com, noting a 35% increase in US sales to AUD$0.8 million for the same period. These strong sales figures are attributed to strategic brand awareness efforts and are expected to grow with a focus on the North American market during the upcoming vacation season.
For further insights into AU:IMC stock, check out TipRanks’ Stock Analysis page.
